Department of Internal Medicine, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Eur J Nutr. 2024 Sep;63(6):2121-2135. doi: 10.1007/s00394-024-03408-9. Epub 2024 May 6.
Recent advances have led to greater recognition of the role of mitochondrial dysfunction in the pathogenesis of chronic kidney disease (CKD). There has been evidence that CKD is also associated with dysbiosis. Here, we aimed to evaluate whether probiotic supplements can have protective effects against kidney injury via improving mitochondrial function.
An animal model of CKD was induced by feeding C57BL/6 mice a diet containing 0.2% adenine. KBL409, a strain of Lactobacillus acidophilus, was administered via oral gavage at a dose of 1 × 10 CFU daily. To clarify the underlying mechanisms by which probiotics exert protective effects on mitochondria in CKD, primary mouse tubular epithelial cells stimulated with TGF-β and p-cresyl sulfate were administered with butyrate.
In CKD mice, PGC-1α and AMPK, key mitochondrial energy metabolism regulators, were down-regulated. In addition, mitochondrial dynamics shifted toward fission, the number of fragmented cristae increased, and mitochondrial mass decreased. These alterations were restored by KBL409 administration. KBL409 supplementation also improved defects in fatty acid oxidation and glycolysis and restored the suppressed enzyme levels involved in TCA cycle. Accordingly, there was a concomitant improvement in mitochondrial respiration and ATP production assessed by mitochondrial function assay. These favorable effects of KBL409 on mitochondria ultimately decreased kidney fibrosis in CKD mice. In vitro analyses with butyrate recapitulated the findings of animal study.
This study demonstrates that administration of the probiotic Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function.
最近的进展使得人们更加认识到线粒体功能障碍在慢性肾脏病(CKD)发病机制中的作用。有证据表明,CKD 也与肠道菌群失调有关。在这里,我们旨在评估益生菌补充剂是否可以通过改善线粒体功能来对肾脏损伤起到保护作用。
通过给予 C57BL/6 小鼠含有 0.2%腺嘌呤的饮食来诱导 CKD 动物模型。嗜酸乳杆菌 KBL409 通过口服灌胃以每天 1×10 CFU 的剂量给药。为了阐明益生菌对 CKD 中线粒体发挥保护作用的潜在机制,用 TGF-β和 p- 对甲酚硫酸盐刺激的原代小鼠肾小管上皮细胞给予丁酸盐。
在 CKD 小鼠中,PGC-1α 和 AMPK,关键的线粒体能量代谢调节剂,下调。此外,线粒体动力学向分裂转移,碎片化嵴的数量增加,线粒体质量减少。这些改变通过 KBL409 给药得到恢复。KBL409 补充还改善了脂肪酸氧化和糖酵解的缺陷,并恢复了 TCA 循环中受抑制的酶水平。因此,通过线粒体功能测定评估,线粒体呼吸和 ATP 产生都得到了改善。KBL409 对线粒体的这些有利影响最终减少了 CKD 小鼠的肾脏纤维化。用丁酸盐进行的体外分析再现了动物研究的结果。
这项研究表明,嗜酸乳杆菌 KBL409 的益生菌给药通过改善线粒体功能来防止肾脏损伤。